Shield Therapeutics

Portfolio

Shield Therapeutics plc is registered in England and Wales. 

Default features description for sign up page.

Careers

Partnerships

Overview

Contact and Locations

Leadership

Announcements

Webinars

Media

Publications

ID/IDA Facts and Figures

Approved Medicine

Corporate Governance

Analysts & Advisors

AIM Rule 26

Stock Information

Investor Overview

Financials

Noto Sans

Shield’s proprietary lead product, ACCRUFeR®/ FeRACCRU®, has been approved for use in the U.S., the EU, the UK, Canada, Australia and Switzerland and  is now indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older. The product has patent coverage until the mid-2030s. The Company has launched ACCRUFeR® in the U.S. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK,  European Union and Canada with marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, for the Republic of Korea, and Japan while actively pursuing additional in-licensing and out-licensing opportunities.

ACCRUFeR®/FeRACCRU® (ferric maltol) Pipeline